Taxed at 592%: The TerrAscend Cannabis Paradox (TSNDF)
Listen to this report
RoboSystems Cannabis Coverage · FY2025 10-K (filed March 12, 2026) + Q1 FY2026 10-Q (May 7, 2026) · CIK 0001778129 · OTC: TSNDF / TSX: TSND · Priced ~$0.69 (June 2026)
1. The Hook
In 2025 TerrAscend earned about five million dollars before tax — and handed the government a twenty-nine-and-a-half-million-dollar tax bill. That is an effective tax rate of 592.0 percent — a figure the company prints, to the decimal, in its own 10-K. Not a typo: the income-tax provision was nearly six times its entire pretax profit. The reason is a single line of the federal tax code — Section 280E — that bars anyone "trafficking" a Schedule I substance from deducting normal business expenses. The 10-K's own rate reconciliation puts the dollar cost of that one line at $26.0 million for the year. TerrAscend runs profitable dispensaries with a 52 percent gross margin, generates positive operating cash flow, and is still reported as a net-loss company partly because it is taxed as if rent, payroll, and marketing simply do not exist.
That is the cognitive dissonance this coverage exists to surface: a roughly $261 million-revenue multi-state cannabis operator, with $68 million of adjusted EBITDA and fifteen straight quarters of positive operating cash flow, trades at sixty-nine cents and a market cap near a quarter-billion dollars — priced like a failing business, taxed like a cartel, and almost entirely uncovered by Wall Street.
2. Company Snapshot
TerrAscend Corp. is a vertically integrated multi-state operator: cultivation, manufacturing, and retail (the Apothecarium and Gage banners; brands include Cookies, Wana, and Legend) across New Jersey, Pennsylvania, Maryland, Ohio, and California. New Jersey and Pennsylvania are the core; Pennsylvania remains a medical-only market, while New Jersey, Maryland, and Ohio carry adult-use. The company files a 10-K with the SEC (it's domiciled in Canada and also lists on the TSX as TSND), which is why its financials sit cleanly in the structured XBRL data this analysis is built on. The most recent filings are the FY2025 10-K (period ended December 31, 2025) and the Q1 FY2026 10-Q (period ended March 31, 2026). The single most important recent operating event: TerrAscend exited Michigan, where its local subsidiary was placed into receivership over roughly $210 million owed to a lender — a drag now reported in discontinued operations.
3. The Financial Story
Start with what's actually working. On a continuing-operations basis, FY2025 net revenue was $260.6 million, down only ~2.8 percent from the recast $268.1 million in 2024 — essentially flat in a year when the broader US market posted its first-ever annual decline. Gross margin improved to 52.3 percent (from 50.7 percent), adjusted EBITDA was $67.8 million (26.0 percent margin), and the business threw off roughly $25 million of free cash flow from continuing operations. This is not a company that can't operate; the retail footprint is strong (its New Jersey Apothecarium stores rank among the state's top 25; five of six Pennsylvania stores rank top-15). Management underscored the durability on the Q1 call: Maryland is running at a ~$75 million annualized rate at high-50s gross margins, Pennsylvania has now grown revenue year-over-year for four straight quarters off a fully built-out cultivation base that needs no incremental capital, and the company has now strung together fifteen consecutive quarters of positive operating cash flow.
Now the distortion. Operating income was $42.0 million. Below that line, interest expense of $28.8 million — a punishing 11 percent of revenue, the residue of cannabis's scarce, expensive capital — left pretax income from continuing operations at just $5.0 million. Then 280E took $29.5 million in tax (the 10-K attributes $26.0 million of it directly to the IRC 280E add-back). The result: a continuing-operations net loss of about $24.5 million, and, once you fold in the Michigan exit, a total GAAP net loss of $81.3 million. The same pattern repeated in Q1 FY2026: $65.5 million revenue, $17.4 million adjusted EBITDA, $3.4 million pretax — and a $10.3 million tax bill, a ~300 percent rate, with management guiding Q2 to another 2–3 percent of year-over-year revenue growth.
So the real health signal here is cash, not GAAP earnings. TerrAscend has now generated positive operating cash flow for fifteen consecutive quarters, and FY2025 GAAP consolidated operating cash flow was about $21.5 million even after the Michigan drag (the company cites ~$34 million from continuing operations). A business that prints positive cash while reporting an $81 million net loss is telling you the loss is largely non-cash and non-operating — impairments, the Michigan deconsolidation, and a tax code untethered from economic profit.
Which brings in the third thread: the boom-bust scar. TerrAscend rode the 2021 capital cycle up and paid for it. Revenue ran from $194 million (2021) to a $317 million peak (2023), then receded as the Michigan exit and price compression bit. The damage shows in write-offs: in 2022 alone the company booked $311 million of impairments ($170 million goodwill + $141 million intangibles), which drove that year's $325 million net loss. Cumulative goodwill and intangible impairments since the peak total roughly $400 million — a near-complete write-off of boom-era acquisition value. What remains is lean: goodwill of $110 million, about 20 percent of $557 million in assets, and a cost base that finally fits the revenue.
4. Catalyst Scenarios — "How the Math Changes"
280E relief is the whole ballgame, and the switch is half-flipped. The 10-K shows section 280E added $26.0 million to the FY2025 tax provision. Strip that out — apply a normal ~21–25 percent rate to the $5.0 million of continuing-operations pretax income, and the tax bill collapses toward $1–3 million — flipping a $24.5 million continuing-ops loss to roughly breakeven-to-small-profit. Management framed the April rescheduling as a "monumental inflection point," with executive chairman Jason Wild noting on the Q1 call that "the most immediate impact will be the elimination of the 280E tax burden on medical cannabis." The nuance that makes TerrAscend interesting: the April 28, 2026 rescheduling moved FDA-approved and state-licensed medical marijuana to Schedule III, which begins to lift 280E on medical income only. TerrAscend's entire Pennsylvania business is medical, and it carries medical revenue in New Jersey, Maryland, and Ohio — so a real slice of relief is available now, while the larger adult-use slice waits on a broad Schedule III order (the contested DEA hearing opens June 29, 2026, with the partial order under a D.C. Circuit stay). Wild went further, flagging "the potential for retroactive tax relief, which could represent a meaningful upside opportunity that is not currently reflected in market valuations" — and a separate Q4 2026 tailwind as the federal psychoactive-hemp ban pushes a $20–30 billion competing market back toward licensed cannabis.
But there's a counterweight unique to this name: TerrAscend is the test case for the downside of moving early. In April 2024 it filed an amended 2020 return claiming $64.2 million in deductions and received an $8.3 million 280E refund. On April 6, 2026 the DOJ sent correspondence seeking repayment of roughly $9.5 million (the refund plus ~$1.2 million of interest), and on May 18, 2026 it sued — the first known 280E clawback. That's the visible tip. The bigger figure is on the balance sheet: by challenging 280E, TerrAscend has built an accrued uncertain-tax liability of about $139 million (Q1 2026), against an unrecognized tax benefit of $187.6 million — both still climbing, and both tied explicitly to its "280E Tax Position." That $139 million is more than half the company's entire market cap, and the IRS is already examining tax years 2021 through 2023. The prospective medical fix does not erase any of it; TerrAscend is now the named defendant in the fight that hangs over an estimated $1.6 billion of industry-wide 280E claims.
Interstate commerce, uplisting, and M&A are the slower-burn catalysts. TerrAscend's footprint is concentrated in the dense Northeast/Mid-Atlantic corridor — high-value, limited-license markets, but exposed to New Jersey's oversupply-driven price compression today. The bigger optionality is Pennsylvania adult-use, repeatedly stalled but a major future unlock for a top-tier PA operator that has already reactivated cultivation capacity in anticipation (realistic window 2027+). On uplisting, management has scheduled an August 24, 2026 shareholder vote to approve a share consolidation as direct preparation for a US exchange listing on the Nasdaq or NYSE — with the chairman saying it's "no longer a question of if, it is a question of when." TerrAscend has been positioning for this since 2022; the proven 2026 playbook (Trulieve's NYSE listing via a medical-only entity) gives it a template. That credibility is feeding the M&A pipeline too: management says acquisition targets — increasingly distressed assets in TerrAscend's own core markets — are more willing to deal because TerrAscend's stock, used as equity or convertible consideration, now has "a higher likelihood of being able to go public on a U.S. exchange in the next, say, 12 to 24 months."
5. Valuation — "What It's Worth If It's a Normal Business"
Today TerrAscend trades around $0.69, a market cap near $253 million and enterprise value near $471 million — roughly 7.0x EV/EBITDA and 1.6–1.8x EV/revenue, at 48 percent of its 52-week high. For context, consumer-staples and "sin" peers that sell legal intoxicants — Constellation Brands (~10–12x EV/EBITDA), Altria (~9x) — trade at meaningfully higher multiples on businesses with worse growth, because they keep their deductions and convert EBITDA to cash. TerrAscend's discount is, in large part, the capitalized cost of 280E and Schedule I.
Cross-sector re-rating lens. TerrAscend's $67.8 million of adjusted EBITDA is already 280E-agnostic (EBITDA sits above the tax line); what 280E destroys is the cash conversion of that EBITDA, which is precisely why the market caps the multiple. Remove the tax penalty and the same EBITDA deserves a staples-like multiple. At 10–14x on $67.8 million, enterprise value runs $680–950 million; netting ~$200 million of net debt leaves equity of roughly $480–750 million, or about $1.20–1.90 per share on a fully diluted basis — versus $0.69 today.
Scenario DCF (assumptions stated, ranges not targets). Discounting free cash flow at an elevated ~14 percent WACC (a Schedule I, OTC-listed microcap) with conservative ~2–3 percent terminal growth: a base case that keeps 280E and soft New Jersey pricing supports roughly today's enterprise value (call it the $0.55–0.75 zone). A partial-catalyst case — medical 280E relief captured, a successful consolidation/uplist that compresses the discount rate — points to roughly $0.85–1.20. A full-catalyst case — broad Schedule III lifting 280E on all income, Pennsylvania adult-use, and a CPG-style re-rating — points to roughly $1.40–1.90. The honest read of the band: at $0.69 the market is pricing close to the base case and assigning little value to catalysts that are real but uncertain. These are implied values under the stated assumptions, not price targets and not advice.
6. Risks and Open Questions
The risks are specific and not generic boilerplate. Broad rescheduling could stall or the partial medical order could be stayed by the D.C. Circuit, in which case the adult-use majority of TerrAscend's income keeps the full 280E burden. The tax overhang is the single biggest one: that ~$139 million accrued 280E back-tax liability — more than half the market cap — is a real, growing claim, not a refund-in-waiting, and the DOJ's $9.5 million clawback plus an active IRS examination of 2021–2023 are the first tests of whether the company keeps the deductions it has been claiming. New Jersey oversupply and price compression — the very markets TerrAscend is most exposed to — could keep deflating wholesale and retail prices; management is deliberately trading some wholesale volume for margin to defend it. On the funded debt, the near term is actually comfortable — management notes no material maturities until late 2028, and the schedule confirms it ($5.5 million due in 2026, $6.0 million in 2027) — but a ~$220 million balloon lands in 2028, and with interest expense of $28.8 million still consuming most of consolidated operating cash flow, that refinancing is the real survival question, not a near-term one. The Michigan receivership (now ~85 percent wound down) is a reminder of how fast a single market can turn into a liability. And the uplisting is a vote and an application, not a done deal. The open question for next quarter: does the medical-relief tailwind start showing up as a falling effective tax rate, and does the August consolidation vote pass cleanly?
7. The Bottom Line
TerrAscend is a cash-generative, top-tier Northeast operator wearing the financial costume of a failing company — and most of that costume is stitched from 280E, impairments, and a Michigan exit, not from the underlying business. The bull case is leverage to a switch that is already half-flipped: every point the effective tax rate falls drops almost dollar-for-dollar to the bottom line, and a clean uplisting would re-rate the whole structure. The bear case is that the switch flips slowly and unevenly, the clawback suit and the $139 million back-tax liability prove the unpaid taxes are real cash, New Jersey keeps compressing, and the 2028 maturity wall forces dilution before the catalysts fully arrive. The framework to watch: the effective tax rate trend, medical vs. adult-use mix, the August 24 consolidation vote, the 280E back-tax liability, and free cash flow against the 2028 maturity. We're not telling you what to do with that — we're telling you the math nobody else is showing you.
Built with RoboSystems — open-source, structured access to SEC filing data for every public company. Set up the same tools in about five minutes at robosystems.ai.